LIR Life Sciences Collaborates with Neuland Labs on Peptide Development

LIR Life Sciences Corp., based in Vancouver, announced a research and development agreement with Neuland Laboratories Ltd. The collaboration aims to develop Cell Penetrating Peptides (CPPs) for LIR's transdermal GLP-1/GIP platform. Neuland Labs, a seasoned CDMO, will provide R&D and testing services for peptide formulations. This partnership allows Neuland Labs to utilize its extensive experience in peptide synthesis.

Initially, Neuland Labs will develop and test novel CPPs for potential use in pharmacokinetic and pharmacodynamic studies. The agreement may extend to further phases, subject to mutual agreements on commercial terms. LIR intends to leverage Neuland's peptide manufacturing capabilities to push forward preclinical evaluations and plan for clinical and commercial advancements.

LIR has also engaged Fairfax Partners Inc. for a digital marketing initiative, with a budget of USD 150,000, spanning three months.